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Abstract Persisters—a drug-tolerant sub-population in an
isogenic bacterial culture—have been featured throughout
the last decade due to their important role in recurrent bacterial
infections. Numerous investigations detail the mechanisms
responsible for the formation of persisters and suggest excit-
ing strategies for their eradication. In this review, we argue
that the very term “persistence” is currently used to describe
a large and heterogeneous set of physiological phenomena
that are functions of bacterial species, strains, growth condi-
tions, and antibiotics used in the experiments. We caution
against the oversimplification of the mechanisms of persis-
tence and urge for a more rigorous validation of the applica-
bility of these mechanisms in each case.
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Introduction
Development of antibiotics is one of the major achievements
of medicine. Unfortunately, this class of drugs is undermined
by bacterial evolution that leads to development of mecha-
nisms that reduce their efficacy. One of these mechanisms is
antibiotic resistance, the ability of a microorganism to grow in
the presence of increasing concentrations of a drug.
Resistance is inheritable and relies on specific genes or muta-
tions, such as genetic changes responsible for modification of
drug binding sites, antibiotic efflux by pumps, modification of
the drug molecule, and others (reviewed by Palmer and
Kishony 2013; Wilson 2014; Blair et al. 2014). Another strat-
egy employed by bacteria to counter antibiotics is tolerance,
i.e., avoiding death by antibiotics. In contrast to the resistant
bacteria, tolerant bacteria are unable to multiply in the pres-
ence of a drug but survive the antibiotic challenge. A special
case of this strategy is the formation of a subset of extremely
tolerant “persister cells.” In an isogenic antibiotic-sensitive
culture, persisters constitute a sub-population that survives
the treatment by bactericidal antibiotics without harboring a
specific antibiotic resistance determinant (Lewis 2010;
Balaban 2011). We argue against approaching the phenome-
non of persistence by applying concepts that are borrowed
directly from the field of antibiotic resistance, i.e., attempting
to reduce the persistence to a single defined trait in a sub-
population that is brought about by specific molecular mech-
anisms. In so doing, the research community has reached a
greatly oversimplified view of persistence. We argue that the
phenomenon of persisters is more complex and that there is no
overarching “general mechanism” that can be applied to all
bacterial species, regardless of the growth conditions or the
class of antibiotic employed.
As a discussion paper, this review touches on only some of
the critical points in the field and does not provide a compre-
hensive overview. For those who are new to this field, we
recommend the excellent reviews by Lewis (2010), Balaban
(2011), Cohen et al. (2013), Maisonneuve and Gerdes (2014),
Amato et al. (2014), and Brauner et al. (2016).
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Persisters, bacterial non-replicating state,
and antibiotic tolerance
Bigger (1944) made the astute observation that penicillin can-
not sterilize bacterial cultures. The surviving bacteria, the
“persisters,” cannot grow in the presence of the drug but re-
sume growth after removal of the antibiotic. In this way, the
persisters differ from resistant cells that can grow in the pres-
ence of the antibiotic (Lewis 2010; Balaban 2011). Because
the cultures started by the surviving cells contain persisters at
the same frequency as the original cultures, we know that
persistence is not genetically inheritable but is due to pheno-
typic diversification (Bigger 1944; Keren et al. 2004a).
Bigger’s seminal work put forward an idea that persisters are
refractory to killing because they are not proliferating; it had
already been established that penicillin does not kill non-
growing cultures (Meyer et al. 1942). The attempts to solve
the riddle of antibiotic persistence in the interim have been
scarce (e.g., Moyed and Bertrand 1983) in spite of the sug-
gested clinical importance of this topic (McDermott 1958).
Revival of the interest in persisters in 2000s started from a
study that suggested a link between survival of a tolerant
sub-population and bacterial biofilm resistance to antimicro-
bials (Lewis 2001; Spoering and Lewis 2001). Newer tech-
niques of single cell analysis (microfluidic devices and flow
cytometry) clearly demonstrated the presence of a non-
growing sub-population within a growing bacterial culture
and that the persisters originate from among these non-
growing bacteria (Balaban et al. 2004; Roostalu et al. 2008;
Jõers et al. 2010). These observations substantiated the hy-
pothesis that persisters are a minor sub-population of bacteria
that maintain a non-replicating state in conditions where most
cells are replicating.
However, not all the non-replicating cells resume
growth and form colonies upon plating that is needed to
define or classify them as persisters. The difference in the
size of the non-growing and persister populations can be
several orders of magnitude. For example, in conditions
where E. coli cultures contain <0.2 % persisters, as deter-
mined by counting colony forming units (CFU), ∼20 %
are non-replicating and not lysed by ampicillin (Roostalu
et al. 2008). These non-replicating and non-lyzing cells
have been physically isolated to analyze their molecular
content (Cañas-Duarte et al. 2014; Keren et al. 2004b;
Keren et al. 2011), although interpolation of these results
onto the “real” persisters that constitute a tiny fraction of
the non-lyzed bacteria that can be identified only after
plating remains speculative. This is also true when a
sub-population of cells is physically separated, based on
some other marker of inactivity or dormancy (Shah et al.
2006). Most of the non-replicating and non-lyzed cells can
be identified as alive using marker dyes that penetrate
only dead cells (Keren et al. 2004b; Roostalu et al. 2008).
In environmental microbiology, non-growing bacteria that
cannot form colonies are referred to as viable but not c-
ulturable (VBNC). They are non-replicating but, in contrast
to the dead microorganisms, retain cell integrity, which is typ-
ically assessed by impermeability to certain fluorescent dyes,
and some degree of metabolism, usually determined with met-
abolic marker dyes (Pinto et al. 2015; Xu et al. 1982; Oliver
2010). In environmental bacterial communities, VBNC bacte-
ria form the majority: only 0.001–1 % of all microbes can be
cultivated on solid media (Bianchi and Giuliano 1996). On
one hand, non-cultivability of environmental bacteria is a
characteristic of certain bacterial species and entire phyla that
cannot be cultured by standard plating methods (Rappé and
Giovannoni 2003). On the other hand, it is a phenotypic trait
of individual bacterial cells of cultivable pathogens and, as
such, has relevance to public health, food technology, and
wastewater treatment (Desmonts et al. 1990; Oliver 2010; Li
et al. 2014; Ayrapetyan et al. 2015a). The term has been also
used to describe bacteria that survive wastewater treatment
processes such as chlorination. Thus, the non-replicating
sub-population encompasses both VBNC cells and persisters
(Li et al. 2014; Ayrapetyan et al. 2015a), which have rarely
been discussed in the same context, although they could form
a “dormancy continuum” (Ayrapetyan et al. 2015b).
Another relevant matter is antibiotic tolerance.
Confusingly, antibiotic tolerance and persistence are often
used as synonyms; indeed, both characterize bacteria that sur-
vive the antibiotic challenge (Kester and Fortune 2014).
However, “antibiotic tolerance,” as used in clinical microbiol-
ogy, describes reduction in the rate of antibiotic-induced kill-
ing of a whole bacterial population (Tomasz et al. 1970;
Tuomanen et al. 1986a), whereas persistence refers to survival
of a small sub-population (Fig. 1). The two phenomena can be
distinguished experimentally by following the time course of
antibiotic killing, which often has a pronounced biphasic na-
ture. During the first phase, the bulk of the population is killed,
Fig. 1 Antibiotic killing kinetics of bacterial cultures showing a rapidly
sterilized culture, tolerance and resistance. The slower killing phase or
plateau is defined as persisters
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followed by a slower phase (or a plateau) corresponding to the
persister fraction. Antibiotic tolerance manifests in slower kill-
ing during the first phase, whereas increased persistence in
high persistence (hip) mutants is reflected in a higher plateau.
However, the trajectories of the killing curves are often more
complex than depicted in Fig. 1 (Lechner et al. 2012), indicat-
ing physiological heterogeneity within persister sub-
populations (Allison et al. 2011a). Persisters can survive anti-
biotic concentrations considerably above the minimum inhib-
itory concentration (MIC). Like the plateau on a time-
dependent killing curve (Fig. 1), a plateau forms on a concen-
tration-dependent killing curve, indicating the range of anti-
biotic concentrations that kills all non-persisters but allows
only the persisters to survive. Analyses of persisters use con-
centrations of antibiotics within the range of the plateau.
Therefore, survival of persisters does not strictly depend on
the antibiotic concentration, whereas the killing rate of the
bulk of bacteria is dependent on antibiotic concentration and
tolerance of the bulk is tested at significantly lower antimicro-
bial concentrations (Tuomanen et al. 1986a; Theodore et al.
2013).
Antibiotic tolerance can be either genotypic or phenotypic.
Genotypic tolerance characterizes clinical isolates and mu-
tants killed at a reduced rate in culture conditions where stan-
dard strains are effectively killed. Phenotypic tolerance occurs
under cultivation conditions resulting in slow bacterial growth
(Meyer et al. 1942; Tuomanen et al. 1986a). For example, the
rate of killing by cell wall synthesis inhibiting antibiotics is
negatively correlated with bacterial growth rate (Tuomanen
et al. 1986a); starving, dormant, non-growing bacterial cul-
tures are tolerant to nearly all antibiotic classes (Tuomanen
et al. 1986b). Thus, like the “dormancy continuum,” there is
also a “tolerance continuum” of microbes having different
genotypes and physiological states. This makes direct com-
parison of data obtained by different research groups in dif-
ferent conditions exceedingly challenging. In order to address
this issue, Brauner and colleagues have put forward a classi-
fication of different aspects of tolerance and persistence in a
recent Opinion article (Brauner et al. 2016).
Dormancy and activity of persisters
Connections between the physiological states of bacteria (in-
cluding persisters) during infection and antibiotic treatment
efficiency are not well characterized, but the evidence of such
a connection is increasing. Since persisters are believed to be a
major cause of the refractoriness of chronic infections, it is
natural to discuss them in a medical context and investigate
this phenomenon in eukaryotic cell cultures and in the relevant
infection models. In these more complex setups, there is great-
er heterogeneity than in test tube cultures. It is noteworthy
that, for Mycobacterium infections in which persisters form
a highly clinically relevant population responsible for the long
duration of antibiotic treatment, non-replicating and actively
replicating bacteria (i.e., phenotypically resistant bacteria) co-
exist (Adams et al. 2011). It is often stated that persisters are
dormant cells with diminished metabolism. This notion
equates non-replicating state with dormancy and lowmetabol-
ic activity. While a fraction of mycobacterial persisters is,
indeed, metabolically dormant, there is also a fraction of cells
that are physiologically active and have extremely efficient
drug efflux which is responsible for their survival of antibiotic
treatment (Adams et al. 2011; Wakamoto et al. 2013). A con-
nection between the efflux activity and persistence has recent-
ly been reported for E. coli (Pu et al. 2016).
In an animal model, Salmonella forms sub-populations
with a wide range of growth rates (Helaine et al. 2014;
Claudi et al. 2014). Dormant cells survive antibiotic treatment
best, with the fastest growing cells being the most sensitive
(Claudi et al. 2014). Dormant cells, although refractory to
antibiotics, are not the major contributors to the progression
of infection because they do not divide. The slowly dividing
cells were the major contributors to the progression of infec-
tion because they are less sensitive than the fast growers. This
suggests that, during an infection, we should not classify bac-
terial cells into persisters and non-persisters because a wide
range of growth rates and antibiotic sensitivity levels develop.
Different types of persisters—are persisters equally
recalcitrant to all classes of antibiotics?
Many investigations show that this is not the case. Early work
showed that hip mutants selected using ampicillin had in-
creased persister levels against fluoroquinolone antibiotics,
and vice-versa (Wolfson et al. 1990), which suggested that
persisters are recalcitrant to several or all antibiotics.
However, later studies indicate that persister levels depend
considerably on the class of antibiotic and different (probably
overlapping) cell populations survive different antibiotics
(Goneau et al. 2014; Amato and Brynildsen 2015). For exam-
ple, bacteria in log phase cultures that are not killed by
fluoroquinolones and cell wall synthesis inhibitors were effec-
tively killed by aminoglycosides (Allison et al. 2011b; Jõers
et al. 2010; Spoering and Lewis 2001). The underlying mech-
anism is well understood; aminoglycoside killing depends on
membrane potential, which is required for the uptake of the
positively charged drugs; stimulation of the potential by me-
tabolites greatly enhances aminoglycoside killing (Allison
et al. 2011b). Another convincing example of the differential
effects of different antibiotic classes on persister killing was
presented in a recent work where a culture was co-treated with
ampicillin and ofloxacin before and after a diauxic shift
(Amato and Brynildsen 2015). Before diauxie, the persister
levels were comparable in co-treatment and separate
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treatments. After the metabolic shift, which induced persister
formation, the persister population of the co-treated sample
was tenfold smaller than after separate treatments with ampi-
cillin and ofloxacin. This suggests that 90 % of the shift-
induced ampicillin and ofloxacin persisters were tolerant to
only one antibiotic and not the other (Amato and Brynildsen
2015).
Can the persister state be induced?
It is often stated that persisters are pre-existing in bacterial
cultures before the antibiotic treatment (Balaban et al. 2004;
Maisonneuve et al. 2013), but does this hold for all antibiotic
classes and can persisters be induced? Generally, all stresses
that temporarily inhibit growth seem to induce persisters. The
diverse stress signals that induce persisters include metabolic
limitations (i.e., secession of growth, reaching a stationary
phase) (Jõers et al. 2010; Luidalepp et al. 2011), nutritional
shifts/diauxie (Amato and Brynildsen 2014, 2015; Amato
et al. 2013; Kotte et al. 2014), expression of toxic proteins
(Vázquez-Laslop et al. 2006), and low concentrations of anti-
biotics (Dörr et al. 2010; Johnson and Levin 2013; Ocampo
et al. 2014). Again, different effects of different antibiotics are
seen; for example, ampicillin seems not to induce dormancy,
whereas fluoroquinolones and aminoglycosides do (Johnson
and Levin 2013; Dörr et al. 2009 2010). Induction of persisters
by antibiotics raises concerns about pharmacokinetics during
an antibiotic treatment regime. It is unavoidable that lower
antibiotic concentrations precede the peak concentration at
the infection site. Moreover, selection consisting of several
rounds of antibiotic treatment resembling the setup of the
Moyed’s pioneering work of hip mutant isolation (Moyed
and Bertrand 1983) is constantly occurring in every chronic
infection treated with antibiotics. Additionally, host factors,
e.g., macrophage phagocytosis (Helaine et al. 2014) and loca-
tion in low-pH compartments (Leimer et al. 2016) constitute
harsh stressors that induce persisters during infection. Indeed,
persisters strike back exactly where we most want to attack
them.
The many roads to persistence—persister formation
as a function of experimental conditions
Killing by antibiotics and growth resumption are strongly in-
fluenced by growth conditions, e.g., different growth media
lead to very different persister levels (Luidalepp et al. 2011;
Varik et al. 2016). We have switched from autoclaving to
filtration as a way of sterilization of rich media because even
minor changes in the autoclaving conditions influence degra-
dation of the ingredients and our experimental results
(Luidalepp et al. 2011; Madar et al. 2013). Since growth rates
are necessary to antibiotic sensitivity of the culture, it is nec-
essary to report the growth curves alongside the persister mea-
surements. In a recent opinion paper, Frederick Neidhardt
urged for standardization and extensive documentation of
the growth conditions used in microbiological studies
(Neidhardt 2006); we strongly support this recommendation.
Persister formation as a function of strain
background
What is true for E. coli is true for the elephant—unless we
study the trunk. Research on experimentally amenable model
organisms is convenient as long as we can extrapolate from
model organisms. Laboratory strains of E. coli, being the most
common models in molecular microbiology, are also the bac-
teria of choice in investigations on persistence.
As laboratory strains of E. coli have preserved the key
components of replication, gene expression, and metabolism,
they naturally have some relevance to biological phenomena
and treatment of infectious diseases. However, the key ques-
tion is, do laboratory E. coli preserve those features of dor-
mancy and growth resumption that are specifically relevant
for persister formation?
First, we need to know the variability in natural E. coli
isolates. Toxin-antitoxin systems are implicated in persister
formation (Keren et al. 2004b; Maisonneuve et al. 2011;
Gerdes and Maisonneuve 2012; Maisonneuve et al. 2013;
Helaine et al. 2014), but they are components of the variable
part of genome. For example, E. coli laboratory K12 and
uropathogenic CFT073 were reported to have only a small
overlap in their complement of toxin-antitoxin genes
(Pandey and Gerdes 2005; Norton and Mulvey 2012). The
high variability of toxin-antitoxin systems between strains
was confirmed when it was shown that even the K-12 strains
can contain between 9 and 16 systems (Makarova et al. 2009).
Although the numbers of annotated toxin-antitoxin systems
have increased over the years, the wider view of high variabil-
ity is unchanged. On top of the natural variation, laboratory
E. coli has been cultivated through numerous growth resump-
tion cycles that might have strongly selected for specific
growth resumption phenotypes (Lenski et al. 1998). Just
how much the laboratory model strains reflect the persisters
observed in clinical setting needs investigating.
The next layer of complications is related to the construc-
tion of knockout strains; complementation of knockouts from
plasmids is the method of choice during strain construction.
This practice is now not widely used as high-throughput
methods emerged. Large collections of knockout strains and
gene inactivation libraries are screened for mutants that have
increased persister levels (Li and Zhang 2007). Similarly,
these collections are often used as a source for strains for more
detailed studies (Luidalepp et al. 2011;Wu et al. 2012). In case
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mutations influence cell growth and growth resumption pa-
rameters that are often the key issues for persister formation,
compensatory mutations are selected. The procedure can re-
sult in different strains in which the inactivated genes are
compensated by different mutations (Shachrai et al. 2011;
Bergmiller et al. 2012). For example, Shachrai et al. (2010)
have studied the E. coli spoT knockout strain, although this
strain is not viable in the absence of compensatory mutations
(Shachrai et al. 2011; Xiao et al. 1991; Montero et al. 2014).
The evolution of compensatory mutations makes interpreta-
tion of the results difficult—the phenotypes measured can be
caused not only by inactivation of the original gene but also by
the compensatory mutations.
A search for the universal molecular mechanism
of persistence
Modern drug development starts with the identification of a
target macromolecule. According to this pharmaceutical logic,
targeting persisters must start with identification of their for-
mation pathway, which would allow development of inhibi-
tors (or activators) against the key components of the pathway.
An assumption here is that a single or a few pathways exist.
The standard method of identifying such a pathway is a
lack-of-function screen of a mutant library. Despite many at-
tempts (De Groote et al. 2009; Hansen et al. 2008; Shan et al.
2015), these screens failed to identify a mutant completely
lacking persisters, which would otherwise be comparable to
asporogenic mutants of endospore-forming bacteria.
Altogether, genetic studies have not pinpointed specialized
persister genes with no role outside persister formation, sug-
gesting a lack of a specialized persister formation pathway.
The identified genes are often pleiotropic, e.g., relA, spoT,
dksA, ssrA, lon, having multiple effects on many different
biological traits. Other genes emerging from the screens are
those involved in metabolism (e.g., sucB, glpD, ubiF) or in
well-defined stress responses (e.g., recA), and their effects on
persister formation are clearly auxiliary. Follow-up studies
based on the findings of the screens show that the effects of
mutations implicated in altered persistence heavily depend on
the particular experimental conditions (Luidalepp et al. 2011).
Because many mutations reduce to some extent persister
levels, combining several knockouts to obtain larger effects
looks tempting, which also allows seeing the effects of redun-
dant genes—as shown for the TA systems (Maisonneuve et al.
2011; Maisonneuve et al. 2013). One difficulty may be the
deviant physiology of the multiple knockout strains; for ex-
ample, the ΔrelA, ΔspoT strains have been used to test the
effect ppGpp on persister formation in both E. coli
(Maisonneuve et al. 2013) and Pseudomonas aeruginosa
(Nguyen et al. 2011), while it is known that such double
mutants result in pronounced growth defects and that they
swiftly pick up compensatory mutations (Montero et al.
2014).
An important question is whether the findings illuminate
universal molecular mechanisms or are restricted to specific
bacterial strains and experimental setups. The role of reactive
oxygen species has been suggested to be a general bactericidal
mechanism of antibiotics (Kohanski et al. 2007). Although the
experimental data were correct under the precise conditions
used, even slight changes in experimental conditions led to
data that undermined the general validity of the concept
(Keren et al. 2013; Liu and Imlay 2013). Avery specific mod-
el for persister formation that involves the signal molecule
ppGpp and toxin-antitoxin systems has been proposed for
E. coli by Maisonneuve et al. (2013). The general validity of
this model remains to be tested in different growth conditions,
and strains before it might be approved as an overarching
concept. For example, persisters are still formed in E. coli
strains lacking enzymes for ppGpp synthesis (Chowdhury
et al. 2016). In addition, a mechanism that does not rely on
toxin-antitoxin systems but senses the intracellular ATP level
has been suggested as a key component for persister formation
in Staphylococcus aureus (Conlon et al. 2016).
Another direction in the search for genetic determinants is
screening for genes and mutants that increase persister levels,
i.e., a gain-of-function screen (Girgis et al. 2012; Spoering
et al. 2006). Both overexpression (Spoering et al. 2006) and
disruption (Girgis et al. 2012) of many genes can considerably
increase persister formation, and persistence is accompanied
by a drop in growth rate. It is a matter of contention whether
bacteria that have been turned into “model persisters” by arti-
ficial overexpression of growth-arresting proteins (Mok et al.
2015; Rotem et al. 2010) are suitable for studying persister
physiology and metabolism.
When Moyed and Bertrand (1983) selected for mutants
with altered persister levels, they tried to exclude indirect ef-
fects of impaired growth by setting requirements for un-
changed growth parameters and MIC, thereby attempting to
select for mutations as specific as possible for a changed per-
sister level. This was forgotten in later screens and character-
ization of natural/clinical isolates, making any interpretation
difficult.
Bet hedging or just damage?
Several bacterial groups form spores, a strategy that evolved
to encounter harmful environmental conditions. It is suggested
that formation of the dormant persisters is also a purposeful
strategy that evolved by natural selection similarly to such
features as lactose metabolism or the formation of flagella.
Stochastic entry of a subset of cells into dormancy and the
spreading with time of their subsequent wake-up might be a
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bet-hedging strategy that allows cells to survive in fluctuating
environments (Grimbergen et al. 2015). Similar patterns of a
signal-induced fall into dormancy (inability to initiate growth
under favorable conditions) and spread of reactivation times
occur across many life forms. These have been described in
plant seed dormancy and germination (Bentsink and
Koornneef 2008), dormancy and sprouting of vegetative un-
derground parts in plant (Sarath et al. 2014), as well as in the
heterogeneity of bacterial sporulation (González-Pastor 2011;
Verplaetse et al. 2015) and spore germination (Sturm and
Dworkin 2015). However, it has to be noted that claiming a
phenomenon “bet hedging” requires careful consideration (de
Jong et al. 2011). As a fashionable concept, it is often used as a
conceptual cornerstone (e.g. Verstraeten et al. 2015), although
it is extremely difficult to prove that the phenomena had
evolved for hedging bets.
An alternative explanation is the Persistence as Stuff
Happens (PaSH) hypothesis advanced by Bruce Levin
(Johnson and Levin 2013; Levin et al. 2014), similar to the
“just damage” mechanism of Nyström and Gustavsson
(1998). These concepts postulate that many mechanisms are
responsible for persistence, just as there are manymechanisms
in mutagenesis. Mutagenesis, damage, and aging cannot be
switched off. Imagine a town attacked by deadly radiation that
kills all the people not in their homes on the day of irradiation.
The vast majority of townspeople to survive would be the sick
and old who remained in bed. According to this model, mak-
ing bacteria sick would increase persister levels, which is what
happens. As already discussed, persister levels are increased
by harmful environmental conditions and many genetic
defects.
Nevertheless, in many circumstances, the persisters have a
clear adaptive value for a bacterial population (Van den Bergh
et al. 2016), for example, by allowing to establish chronic
infections. Increase in persister levels of P. aeruginosa clinical
isolates from cystic fibrosis patients implies that hip mutants
are selected in chronic patients (Mulcahy et al. 2010); similar
observation was made for the isolates of pathogenic yeasts
(Lafleur et al. 2010) and clinical isolates of S. aureus (Gao
et al. 2010) and E. coli (Schumacher et al. 2015). It seems that
both the adaptation and the PaSH mechanisms are used by
different strains and under different conditions, and these
may even sometimes operate in parallel.
Perspectives
In accepting the PaSH hypothesis and that we cannot switch
off persister formation pharmaceutically, how should persister
research and the development of anti-persister therapy pro-
ceed? In the light of recent research on human microbiota that
shows its strong impact on the immune system and health in
general, it would be unreasonable to conceive of drugs that
indiscriminately kill bugs and leave a patient germ free.
Rather, persisters of our healthy microbiota are extremely
valuable for restoring it after an antibiotic regime. Therefore,
development of drugs and treatments that specifically target
particular chronic infections (sensitive bacteria + persisters)
seems to be the most promising approach. There are already
some preclinical examples of such approach. In a recent study,
Conlon et al. recognized the unique ability of ADEP
(acyldepsipeptide) to target a stationary population of
S. aureus that was insensitive to a range of antibiotics
(Conlon et al. 2013). ADEP activates and dysregulates prote-
ase ClpP by opening up the proteolytic interior of the enzyme.
Development of the drug was not pursued because bacteria
acquire resistance at a high frequency (1 × 10−6) to the com-
pound due to null mutation of the non-essential clpP gene.
However, ADEP in combination with rifampicin eradicated
the population and could sterilize a deep-seated murine thigh
infection model of S. aureus.
More research of the mechanisms underlying persisters is
clearly needed, which would be expected to lead to improved
antibiotics and treatment regimes. Two important points need
to be emphasized: (i) the phenomenon should not be
oversimplified, we should not hurry into the molecular mech-
anisms before the empirical aspects of persistence are de-
scribed andmodel systems validated and, therefore, (ii) further
research on animal infection models is required as only this
can indicate which in vitro observations are relevant regarding
any possible (clinical) therapeutic measure.
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